Introduction
Materials and methods
Ethics statement
Study participants
Inclusion criteria
Exclusion criteria
Sample and data collection
Ki-67 index detection
Follow-up
Statistical analysis
Results
Clinical baseline characteristics
Parameters | Good prognosis group (N = 235) | Poor prognosis group (N = 55) | P |
---|---|---|---|
Age (year) | 66.46 ± 5.21 | 67.53 ± 4.61 | 0.1637 |
Hypertension | |||
No | 165 (70.21%) | 39 (70.91%) | 0.6694 |
Yes | 70 (29.79%) | 16 (29.09%) | |
Diabetes | |||
No | 190 (80.85%) | 45 (81.82%) | 0.8692 |
Yes | 45 (19.15%) | 10 (18.18%) | |
PSA (ng/mL) | |||
< 20 | 140 (59.57%) | 20 (36.36%) | 0.0018 |
≥ 20 | 95 (40.43%) | 35 (63.64%) | |
Gleason score | |||
< 8 | 135 (57.45%) | 22 (40.00%) | 0.0194 |
≥ 8 | 100 (42.55%) | 33 (60.00%) | |
T stage | |||
T2 | 109 (46.38%) | 16 (29.09%) | 0.0197 |
T3-4 | 126 (53.62%) | 39 (70.91%) | |
Lymph node metastasis | |||
No | 144 (61.28%) | 25 (45.45%) | 0.0322 |
Yes | 91 (38.72%) | 30 (54.55%) | |
Seminal vesicle invasion | |||
No | 137 (58.30%) | 24 (43.64%) | 0.0489 |
Yes | 98 (41.70%) | 31 (56.36%) | |
Neutrophils (×109/L) | 3.31 (1.24,5.21) | 3.62 (2.28,5.48) | 0.0166 |
Lymphocytes (×109/L) | 1.84 (0.80,3.25) | 1.45 (0.82,2.41) | < 0.0001 |
Platelets (×109/L) | 229 (163,355) | 284 (207,332) | < 0.0001 |
Preoperative SII | 423.70 (117.10,1197) | 692.10 (275.7,1275) | < 0.0001 |
Ki-67 index | 13.84 ± 2.47 | 18.14 ± 3.38 | < 0.0001 |
Relationship between preoperative SII and Ki-67 index with clinicopathological data in patients with PCa
Parameters | SII low expression group (N = 145) | SII high expression group (N = 145) | P | Ki-67 low expression group (N = 145) | Ki-67 high expression group (N = 145) | P |
---|---|---|---|---|---|---|
PSA (ng/mL) | ||||||
< 20 | 90 (62.07%) | 70 (48.28%) | 0.0182 | 89 (61.38%) | 71 (48.97%) | 0.0336 |
≥ 20 | 55 (37.93%) | 75 (51.72%) | 56 (38.62%) | 74 (51.03%) | ||
Gleason score | ||||||
< 8 | 76 (52.41%) | 81 (55.86%) | 0.5557 | 88 (60.69%) | 69 (47.59%) | 0.0251 |
≥ 8 | 69 (47.59%) | 64 (44.14%) | 57 (39.31%) | 76 (52.41%) | ||
T stage | ||||||
T2 | 65 (44.83%) | 60 (41.38%) | 0.5533 | 62 (42.76%) | 63 (43.45%) | 0.9056 |
T3-4 | 80 (55.17%) | 85 (58.62%) | 83 (57.24%) | 82 (56.55%) | ||
Lymph node metastasis | ||||||
No | 91 (62.76%) | 78 (53.79%) | 0.1216 | 93 (64.14%) | 76 (52.41%) | 0.0429 |
Yes | 54 (37.24%) | 67 (46.21%) | 52 (35.86%) | 69 (47.59%) | ||
Seminal vesicle invasion | ||||||
No | 78 (53.79%) | 83 (57.24%) | 0.5546 | 83 (57.24%) | 78 (53.79%) | 0.5546 |
Yes | 67 (46.21%) | 62 (42.76%) | 62 (42.76%) | 67 (46.21%) | ||
Neutrophils (× 109/L) | 2.84 ± 0.75 | 3.78 ± 0.71 | < 0.0001 | 3.34 ± 0.85 | 3.28 ± 0.89 | 0.5097 |
Lymphocytes (× 109/L) | 2.12 (1.25,3.25) | 1.48 (0.80,2.33) | < 0.0001 | 1.86 (0.80,3.25) | 1.68 (0.82,3.02) | 0.0042 |
Platelets (× 109/L) | 227.50 ± 25.73 | 251.80 ± 36.22 | < 0.0001 | 229.0 (163,355) | 242.0 (167,332) | 0.0336 |
Logistics multivariate regression analysis of the prognosis of PCa patients after LRP
Factor | P | OR | 95% CI |
---|---|---|---|
PSA | 0.167 | 0.526 | 0.211–1.309 |
Gleason score | 0.258 | 0.590 | 0.236–1.472 |
T stage | 0.677 | 0.820 | 0.322–2.086 |
Lymph node metastasis | 0.859 | 0.919 | 0.361–2.335 |
Seminal vesicle invasion | 0.018 | 0.315 | 0.121–0.818 |
Preoperative SII (× 102) | 0.000 | 2.009 | 1.594–2.529 |
Ki-67 index | 0.000 | 1.789 | 1.475–2.171 |
Predictive value of preoperative SII combined with Ki-67 index for poor prognosis after LRP
Pairwise comparison of ROC curves | P |
---|---|
Preoperative SII vs. Ki-67 index | 0.9762 |
Preoperative SII vs. Preoperative SII + Ki-67 index | 0.0002 |
Ki-67 index vs. Preoperative SII + Ki-67 index | 0.0005 |
High preoperative SII + Ki-67 index level increased the risk of poor prognosis in PCa patients after LRP
SII low expression group (N = 204) | SII high expression group (N = 86) | Ki-67 low expression group (N = 162) | Ki-67 high expression group (N = 128) | SII-Ki-67 low expression group (N = 195) | SII-Ki-67 high expression group (N = 95) | |
---|---|---|---|---|---|---|
Good prognosis | 193 (94.61%) | 42 (48.84%) | 155 (95.68%) | 80 (62.50%) | 191 (97.95%) | 44 (46.32%) |
Poor prognosis | 11 (5.39%) | 44 (51.16%) | 7 (4.32%) | 48 (37.50%) | 4 (2.05%) | 51 (53.68%) |
P | < 0.0001 | < 0.0001 | < 0.0001 |